• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝切除术后门静脉血栓形成的患病率及危险因素:一项系统评价和荟萃分析

Prevalence and risk factors of portal vein thrombosis following hepatectomy: a systematic review and meta‑analysis.

作者信息

Qun Yang, Meiying Feng, Weiming Yao, Dan He

机构信息

Department of General Surgery, Jingdezhen Hospital of Traditional Chinese Medicine, Jingdezhen, Jiangxi, China.

Department of General Surgery and Clinical Nutrition, Jingdezhen Hospital of Traditional Chinese Medicine, Jingdezhen, Jiangxi, China.

出版信息

Wideochir Inne Tech Maloinwazyjne. 2025 Jan 15;20(1):36-43. doi: 10.20452/wiitm.2025.17929. eCollection 2025 Apr 9.

DOI:10.20452/wiitm.2025.17929
PMID:40547829
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12177353/
Abstract

INTRODUCTION

The prevalence and risk factors of portal vein thrombosis (PVT) are largely unclear, with an increasing number of studies reporting inconsistent results.

AIM

The current study aimed to evaluate the prevalence and risk factors of PVT following hepatectomy through a systematic review and meta‑analysis.

MATERIALS AND METHODS

A comprehensive literature search was conducted across multiple databases (PubMed, Embase, and the Cochrane Library) to identify relevant studies. Prospective and retrospective studies reporting on PVT following hepatectomy were included. The Newcastle‑Ottawa Scale (NOS) was used to assess study quality, and the random effects model was used to analyze the prevalence and risk factors.

RESULT

A total of 15 studies involving 5145 patients were included in the current meta‑analysis. The pooled prevalence of PVT following hepatectomy was 9% (95% CI, 7%-12%) with substantial heterogeneity (I2 = 93.1%). Subgroup analyses showed that a prospective design and larger sample size were associated with lower prevalence rates. PVT prevalence was higher among the patients undergoing simultaneous splenectomy and hepatectomy. Liver cirrhosis (odds ratio [OR], 5.18; 95% CI, 1.85-14.47), portal vein resection (OR, 5.07; 95% CI, 2.2-11.66), and right‑sided hepatectomy (OR, 6.26; 95% CI, 1.8-21.76) were significant risk factors for PVT.

CONCLUSIONS

PVT is a notable complication following hepatectomy, with an overall prevalence of 9%. Specific factors that significantly increase the risk of PVT include liver cirrhosis, portal vein resection, and right‑sided hepatectomy.

摘要

引言

门静脉血栓形成(PVT)的患病率和危险因素在很大程度上尚不清楚,越来越多的研究报告结果不一致。

目的

本研究旨在通过系统评价和荟萃分析评估肝切除术后PVT的患病率和危险因素。

材料与方法

在多个数据库(PubMed、Embase和Cochrane图书馆)中进行全面的文献检索,以确定相关研究。纳入报告肝切除术后PVT的前瞻性和回顾性研究。采用纽卡斯尔-渥太华量表(NOS)评估研究质量,采用随机效应模型分析患病率和危险因素。

结果

本荟萃分析共纳入15项研究,涉及5145例患者。肝切除术后PVT的合并患病率为9%(95%CI,7%-12%),存在显著异质性(I2 = 93.1%)。亚组分析表明,前瞻性设计和更大的样本量与较低的患病率相关。同时行脾切除术和肝切除术的患者中PVT患病率较高。肝硬化(优势比[OR],5.18;95%CI,1.85-14.47)、门静脉切除(OR,5.07;95%CI,2.2-11.66)和右半肝切除术(OR,6.26;95%CI,1.8-21.76)是PVT的显著危险因素。

结论

PVT是肝切除术后的一种显著并发症,总体患病率为9%。显著增加PVT风险的特定因素包括肝硬化、门静脉切除和右半肝切除术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f41d/12177353/af5a4aa38cc1/vomt-20-1-17929-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f41d/12177353/77de3f912df1/vomt-20-1-17929-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f41d/12177353/78df2329a345/vomt-20-1-17929-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f41d/12177353/beafacdd4f3d/vomt-20-1-17929-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f41d/12177353/af5a4aa38cc1/vomt-20-1-17929-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f41d/12177353/77de3f912df1/vomt-20-1-17929-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f41d/12177353/78df2329a345/vomt-20-1-17929-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f41d/12177353/beafacdd4f3d/vomt-20-1-17929-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f41d/12177353/af5a4aa38cc1/vomt-20-1-17929-g4.jpg

相似文献

1
Prevalence and risk factors of portal vein thrombosis following hepatectomy: a systematic review and meta‑analysis.肝切除术后门静脉血栓形成的患病率及危险因素:一项系统评价和荟萃分析
Wideochir Inne Tech Maloinwazyjne. 2025 Jan 15;20(1):36-43. doi: 10.20452/wiitm.2025.17929. eCollection 2025 Apr 9.
2
Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis.肝硬化门静脉血栓形成的流行病学:系统评价和荟萃分析。
Eur J Intern Med. 2022 Oct;104:21-32. doi: 10.1016/j.ejim.2022.05.032. Epub 2022 Jun 7.
3
Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis.血小板计数、脾脏长度以及血小板计数与脾脏长度之比在慢性肝病或门静脉血栓形成患者食管静脉曲张诊断中的应用
Cochrane Database Syst Rev. 2017 Apr 26;4(4):CD008759. doi: 10.1002/14651858.CD008759.pub2.
4
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤:系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
5
Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis.肝硬化合并门静脉血栓形成患者抗凝治疗的效果:系统评价和荟萃分析。
Gastroenterology. 2017 Aug;153(2):480-487.e1. doi: 10.1053/j.gastro.2017.04.042. Epub 2017 May 4.
6
Efficacy and safety of different options for liver regeneration of future liver remnant in patients with liver malignancies: a systematic review and network meta-analysis.不同方案促进肝脏恶性肿瘤患者剩余肝再生的疗效和安全性的系统评价和网络荟萃分析。
World J Surg Oncol. 2022 Dec 16;20(1):399. doi: 10.1186/s12957-022-02867-w.
7
The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression.非酒精性肝病患者小肠细菌过度生长的患病率:NAFLD、NASH、纤维化、肝硬化-系统评价、荟萃分析和荟萃回归。
Nutrients. 2022 Dec 9;14(24):5261. doi: 10.3390/nu14245261.
8
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
9
Left Upper Lobectomy for Lung Cancer as a Risk Factor for Cerebral Infarction: A Systematic Review and Meta-Analysis.肺癌左上叶切除术作为脑梗死的一个危险因素:一项系统评价和荟萃分析。
Lung. 2021 Oct;199(5):535-547. doi: 10.1007/s00408-021-00480-4. Epub 2021 Sep 27.
10
Effectiveness and safety of vitamin D in relation to bone health.维生素D对骨骼健康的有效性与安全性。
Evid Rep Technol Assess (Full Rep). 2007 Aug(158):1-235.

本文引用的文献

1
Clinical characteristics and predictors of benign portal vein thrombosis in patients with liver cirrhosis: A retrospective single-center study.肝硬化患者良性门静脉血栓形成的临床特征及预测因素:一项回顾性单中心研究。
Medicine (Baltimore). 2024 Sep 20;103(38):e39823. doi: 10.1097/MD.0000000000039823.
2
Impact of anticoagulation therapy on outcomes in patients with cirrhosis and portal vein thrombosis: A large-scale retrospective cohort study.抗凝治疗对肝硬化合并门静脉血栓形成患者结局的影响:一项大规模回顾性队列研究。
Thromb Res. 2024 Sep;241:109103. doi: 10.1016/j.thromres.2024.109103. Epub 2024 Jul 23.
3
Predictors of portal vein thrombosis after simultaneous hepatectomy and splenectomy: A single-center retrospective study.
同期肝切除术和脾切除术后门静脉血栓形成的预测因素:一项单中心回顾性研究。
Asian J Surg. 2024 Dec;47(12):5137-5142. doi: 10.1016/j.asjsur.2024.07.131. Epub 2024 Jul 25.
4
Analysis of factors related to recanalization of portal vein thrombosis in liver cirrhosis: a retrospective cohort study.肝硬化门静脉血栓再通相关因素分析:一项回顾性队列研究。
BMC Gastroenterol. 2024 Jul 13;24(1):224. doi: 10.1186/s12876-024-03322-8.
5
Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies.门静脉血栓形成:诊断、治疗和未来临床研究的终点。
Lancet Gastroenterol Hepatol. 2024 Sep;9(9):859-883. doi: 10.1016/S2468-1253(24)00155-9. Epub 2024 Jul 9.
6
Metabolic dysfunction-associated steatotic liver disease related cirrhosis and incidence of portal vein thrombosis.代谢相关脂肪性肝病相关肝硬化及门静脉血栓形成的发生率。
Eur J Gastroenterol Hepatol. 2024 Aug 1;36(8):1038-1045. doi: 10.1097/MEG.0000000000002800. Epub 2024 May 30.
7
Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH.心房颤动卒中预防和肝硬化门静脉血栓形成及静脉血栓栓塞症抗凝治疗:来自 ISTH 的 SSC 指南。
J Thromb Haemost. 2024 Sep;22(9):2653-2669. doi: 10.1016/j.jtha.2024.05.023. Epub 2024 May 31.
8
Portal Vein Thrombosis in the Setting of Cirrhosis: Evaluation and Management Strategies.肝硬化背景下的门静脉血栓形成:评估与管理策略
Gastroenterology. 2024 Sep;167(4):664-672. doi: 10.1053/j.gastro.2024.05.017. Epub 2024 May 25.
9
Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis.依度沙班治疗肝硬化相关门静脉血栓的疗效。
Sci Rep. 2024 May 11;14(1):10784. doi: 10.1038/s41598-024-60235-y.
10
Impact of Cirrhosis Etiology on the Risk for Venous Thromboembolism.肝硬化病因对静脉血栓栓塞风险的影响
Dig Dis Sci. 2024 Jul;69(7):2691-2698. doi: 10.1007/s10620-024-08440-7. Epub 2024 May 3.